Monday 23 September 2019 ,
Monday 23 September 2019 ,
Latest News
  • 5 JMB men jailed in Aug 17 bomb attack case
  • UK announces extra £87 mn funding for Rohingya crisis
  • DNCC launches drive to free roads, footpaths
  • Trump to join Indian-American extravaganza in Modi bromance
  • Rifat murder: Minni meets lawyer in Dhaka
20 May, 2019 00:00 00 AM

FDA approves Dengvaxia (dengue vaccine) for the prevention of dengue disease in endemic regions

FDA
FDA approves Dengvaxia (dengue vaccine) for the prevention of dengue disease in endemic regions

The U.S. Food and Drug Administration announced recently the approval of Dengvaxia, the first vaccine approved for the prevention of dengue disease caused by all dengue virus serotypes (1, 2, 3 and 4) in people ages 9 through 16 who have laboratory-confirmed previous dengue infection and who live in endemic areas. Dengue is endemic in the U.S. territories of American Samoa, Guam, Puerto Rico and the U.S. Virgin Islands.

“Dengue disease is the most common mosquito-borne viral disease in the world and global incidence has increased in recent decades,” said Anna Abram, FDA deputy commissioner for policy, legislation, and international affairs.

“The FDA is committed to working proactively with our partners at the U.S. Centers for Disease Control and Prevention, as well as international partners, including the World Health Organization, to combat public health threats, including through facilitating the development and availability of medical products to address emerging infectious diseases.

While there is no cure for dengue disease, today’s approval is an important step toward helping to reduce the impact of this virus in endemic regions of the United States."

The CDC estimates more than one-third of the world’s population is living in areas at risk for infection by dengue virus which causes dengue fever, a leading cause of illness among people living in the tropics and subtropics. The first infection with dengue virus typically results in either no symptoms or a mild illness that can be mistaken for the flu or another viral infection.

A subsequent infection can lead to severe dengue, including dengue hemorrhagic fever (DHF), a more severe form of the disease that can be fatal. Symptoms may include stomach pain, persistent vomiting, bleeding, confusion and difficulty breathing.

Approximately 95 percent of all severe/hospitalized cases of dengue are associated with second dengue virus infection. Because there are no specific drugs approved for the treatment of dengue disease, care is limited to the management of symptoms.

Each year, an estimated 400 million dengue virus infections occur globally according to the CDC. Of these, approximately 500,000 cases develop into DHF, which contributes to about 20,000 deaths, primarily among children. Although dengue cases are rare in the continental U.S., the disease is regularly found in American Samoa, Puerto Rico, Guam, the U.S. Virgin Islands, as well as Latin America, Southeast Asia and the Pacific islands.

“Infection by one type of dengue virus usually provides immunity against that specific serotype, but a subsequent infection by any of the other three serotypes of the virus increases the risk of developing severe dengue disease, which may lead to hospitalization or even death,” said Peter Marks, M.D., director of the FDA’s Center for Biologics Evaluation and Research.

“As the second infection with dengue is often much more severe than the first, the FDA’s approval of this vaccine will help protect people previously infected with dengue virus from subsequent development of dengue disease.”

The safety and effectiveness of the vaccine was determined in three randomized, placebo-controlled studies involving approximately 35,000 individuals in dengue-endemic areas, including Puerto Rico, Latin America and the Asia Pacific region.

The vaccine was determined to be approximately 76 percent effective in preventing symptomatic, laboratory-confirmed dengue disease in individuals 9 through 16 years of age who previously had laboratory-confirmed dengue disease. Dengvaxia has already been approved in 19 countries and the European Union.

The most commonly reported side effects by those who received Dengvaxia were headache, muscle pain, joint pain, fatigue, injection site pain and low-grade fever. The frequency of side effects was similar across Dengvaxia and placebo recipients and tended to decrease after each subsequent dose of the vaccine.

Dengvaxia is not approved for use in individuals not previously infected by any dengue virus serotype or for whom this information is unknown. This is because in people who have not been infected with dengue virus, Dengvaxia appears to act like a first dengue infection – without actually infecting the person with wild-type dengue virus – such that a subsequent infection can result in severe dengue disease.

Therefore, health care professionals should evaluate individuals for prior dengue infection to avoid vaccinating individuals who have not been previously infected by dengue virus.

This can be assessed through a medical record of a previous laboratory-confirmed dengue infection or through serological testing (tests using blood samples from the patient) prior to vaccination.

Dengvaxia is a live, attenuated vaccine that is administered as three separate injections, with the initial dose followed by two additional shots given six and twelve months later.

The FDA granted this application Priority Review and a Tropical Disease Priority Review Voucher under a program intended to encourage development of new drugs and biologics for the prevention and treatment of certain tropical diseases. The approval was granted to Sanofi Pasteur.

 

Comments

Most Viewed
Digital Edition
More story
Editor Speaks

Editor Speaks

In Bangladesh, snake bite is common especially in rainy season with incidence density one of the highest in the world, which is around 623.4/100,000 persons…
Snakes and snake bites

Snakes and snake bites

Introduction I have spent long 14 years in Africa including 2 years in East Africa and 12 years in North Africa and have experience of seeing and treating…
NCDC guideline: Management of snakebite in Bangladesh

NCDC guideline: Management of snakebite in Bangladesh

Snakes and snakebites have been known to the people of Bangladesh since ancient time. Snakebite results most often from an unfortunate accidental interaction…
Prevalence of snakebite envenoming

Prevalence of snakebite envenoming

One of the consequences of inadequate efforts to control snakebite envenoming in the past is that the available epidemiological data are fragmented and…
Why are so many people still dying from snake bites?

Why are so many people still dying from snake bites?

DR NICK CASEWELL & DR STUART AINSWORTH   Tens of thousands of people die from snake bites worldwide every year. Lack of treatment and even the…
What you should know about chronic pain

What you should know about chronic pain

Pain. It’s a small, four-letter word that can occupy such a huge part of some people’s lives. The country asks for a month of awareness and…
What is the anti-inflammatory diet?

What is the anti-inflammatory diet?

AMANDA CAPRITTO The anti-inflammatory diet is based on a pretty sound and simple claim: Chronic inflammation leads to chronic disease, and reducing inflammation…
Sudden cardiac deaths can be prevented with advanced cardiac devices

Sudden cardiac deaths can be prevented with advanced cardiac devices

September 2019, Majority of public can’t differentiate between a heart attack and sudden cardiac arrest. Heart Attack is a blood circulation problem…
Common cold stopped by experimental approach

Common cold stopped by experimental approach

JAMES GALLAGHER  Scientists think they have found a way to stop the common cold and closely related viruses which can cause paralysis. Instead of…
FDA approves Rinvoq (upadacitinib), an oral JAK inhibitor for the treatment of moderate to severe rheumatoid arthritis

FDA approves Rinvoq (upadacitinib), an oral JAK inhibitor for the treatment of moderate to severe rheumatoid arthritis

AbbVie, a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved Rinvoq (upadacitinib),…

Copyright © All right reserved.

Editor : M. Shamsur Rahman

Published by the Editor on behalf of Independent Publications Limited at Media Printers, 446/H, Tejgaon I/A, Dhaka-1215.
Editorial, News & Commercial Offices : Beximco Media Complex, 149-150 Tejgaon I/A, Dhaka-1208, Bangladesh. GPO Box No. 934, Dhaka-1000.

Editor : M. Shamsur Rahman
Published by the Editor on behalf of Independent Publications Limited at Media Printers, 446/H, Tejgaon I/A, Dhaka-1215.
Editorial, News & Commercial Offices : Beximco Media Complex, 149-150 Tejgaon I/A, Dhaka-1208, Bangladesh. GPO Box No. 934, Dhaka-1000.

Disclaimer & Privacy Policy
....................................................
About Us
....................................................
Contact Us
....................................................
Advertisement
....................................................
Subscription

Powered by : Frog Hosting